Equity Research, Broker Reports, and media content on MaxCyte, Inc.

  • Access the latest forecasts, broker valuations, multiples, and video content from the city about MaxCyte, Inc.
  • See live updates from analysts, company announcements, and other news in a personalised/single dashboard
  • 13 Mar 24
Hybridan Small Cap Feast - 13 Mar 2024

13th March 2024 * A corporate client of Hybridan LLP ** Arranged by type of listing and date of announcement *** Alphabetically arranged **** Potential means Intention to Float (ITF) has been announced Dish of the day Admissions: Delistings: What’s baking in the oven? ** Potential**** Initial Public Offerings: Reverse Takeovers: Change of Market: Our daily digest of news from UK Small Caps If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”. Hybridan Chefs

Companies: SSIT SAR IXI GYM MMAG MXCT MXCS CORA

Hybridan
  • 18 May 23
Maxcyte (MXCT) - Vox Markets Fund Manager Series: Q&A with Amati Global Investors fund manager, Dr Paul Jourdan
maxcyte-mxct-vox-markets-fund-manager-series-q-a-with-amati-global-investors-fund-manager-dr-paul-jourdan-18-05-2023
  • 11 May 23
Hybridan Small Cap Feast - 11 May 23

11th May 2023 @HybridanLLP Status of this Note and Disclaimer This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectiv

Companies: SENX SAVE MEN MXCT MXCS IMM ING IKA CCS CCT

Hybridan
  • 29 Sep 22
Trinity Delta Lighthouse: MaxCyte

Trinity Delta view: MaxCyte is approaching a landmark with the first regulatory filings for a programme under an SPL. We anticipate a first regulatory decision by year-end 2023 at the earliest. If approved, and pending payor/reimbursement discussions, the first launch of an SPL asset could occur in 2024. Exa-cel approval would have a major impact on MaxCyte’s FY24 revenues given that milestones for BLA/MAA approval are understood to typically be mid-seven figures (potentially per major region),

Companies: CRSP VRTX VRTX CRSP MXCT MXCS

Trinity Delta
  • 06 Sep 22
MaxCyte: Strategic investments to support partners & future growth

MaxCyte’s H122 total revenue of $21.2m grew 56% year-on-year, with core Cell Therapy and Drug Discovery revenues up 46.5% to $19.2m, prompting management to increase FY22 guidance to c 30% core business revenue growth. Guidance for the inherently lumpier programme-related revenues from Strategic Platform Licences (SPLs) remains at c $4m for FY22. First regulatory filings for the most advanced SPL asset, CRISPR Therapeutics’ exa-cel (CTX001) should occur in Q422, meaning a first approval decision

Companies: MaxCyte, Inc. (MXCT:NAS)MaxCyte, Inc. (MXCT:LON)

Trinity Delta
  • 23 May 22
Trinity Delta Lighthouse: MaxCyte

Trinity Delta view: MaxCyte remains well positioned and well-funded to continue to support and expand the adoption of its enabling technologies and expertise in cellular based research and development of next-generation gene edited cell therapies. Q122 revenues indicate both robust demand from cell therapy customers and the implied clinical progress at SPL partners. FY22 guidance for the core business is now ahead of MaxCyte’s five-year revenue CAGR (2017-21) of c 23%. We continue to view MaxCyt

Companies: MaxCyte, Inc. (MXCT:NAS)MaxCyte, Inc. (MXCT:LON)

Trinity Delta
  • 10 May 22
FTSE 100 opens up in spite of more heavy losses on Wall Street overnight with Melrose Industries top
ftse-100-opens-up-in-spite-of-more-heavy-losses-on-wall-street-overnight-with-melrose-industries-top
  • 06 Apr 22
MaxCyte: Sustained FY21 growth with significantly more potential

FY21 revenues were up 30% to $33.9m, demonstrating continued robust growth in MaxCyte’s core Cell Therapy and Drug Discovery businesses (+37% to $31.4m), with management guiding to 22-25% core business revenue growth for FY22. Programme-related revenues from Strategic Platform Licences (SPLs) are inherently lumpier ($2.5m received in FY21; c $4m expected for FY22) but should begin to smooth as the frequency and size of milestone receipts increase as the underlying programmes progress through the

Companies: MaxCyte, Inc.

Trinity Delta
  • 09 Mar 22
MaxCyte: Opening the next chapter

MaxCyte’s NASDAQ IPO heralds the start of a new era. Cash of c $256m (at end-Q321) will fund investment in consolidating and expanding its leading position in non-viral cell delivery and engineering. Increased pipeline visibility under its 16 current Strategic Platform Licences (SPLs), with four secured in 2021 and one YTD in 2022, increases confidence of a significant step up in potential revenue growth from 2023+ as milestone receipts start to smooth and more meaningfully augment core recurrin

Companies: MaxCyte, Inc.

Trinity Delta
  • 03 Dec 21
Maxcyte (AIM:MXCT) - Doug Doerfler, CEO Presenting at the Proactive One2One Virtual Forum - Dec 2021
maxcyte-aim-mxct-doug-doerfler-ceo-presenting-at-the-proactive-one2one-virtual-forum-dec-2021
  • 04 Nov 21
Nkarta signs SPL to accelerate its NK cell therapies

▪ Nkarta Therapeutics has entered into a strategic platform licence (SPL) agreement to gain clinical and commercial rights to use MaxCyte’s Flow Electroporation technology and the ExPERT platform. This nonexclusive licence is the fifteenth such deal and, in common with the prior licences, the financial terms are not disclosed. MaxCyte will receive platform licensing fees and programme-related milestone payments. ▪ Nkarta’s cell therapy approach is based on Natural Killer (NK) cells, which, unlik

Companies: MaxCyte, Inc.

Trinity Delta
  • 29 Apr 21
Maxcyte revenues rise 21%, hailing three new strategic licences with cell therapy developers
maxcyte-revenues-rise-21-hailing-three-new-strategic-licences-with-cell-therapy-developers
  • 29 Apr 21
MaxCyte: 2020 revenues up 21% as industry enters new growth era

MaxCyte (MXCT) is maintaining excellent commercial momentum across its cell therapy business, which led to 21% year-on-year top-line growth to US$26.2mln in fiscal (FY) 2020. This included three new strategic licences with high profile cell therapy developers, a fourth signed post period, a rise in

Companies: MaxCyte, Inc.

Proactive
  • 27 Apr 21
Catching an unbroken wave

MaxCyte’s strong FY20 performance was flagged in February’s trading statement. Revenues were up 21% to $26.2m despite known COVID impacts. EBITDA grew by 121% to $2.9m, before CARMA expenses, driven primarily by lower COVID spend due to pandemic-related restrictions. Potential pre-commercialisation milestones increased from >$800m to >$950m, with 140+ partnered programmes and 100+ covered by clinical licences. This operational momentum is expected to flow into FY21, with sustained revenue growth

Companies: MaxCyte, Inc.

Trinity Delta
  • 08 Feb 21
Better visibility brings future into focus

MaxCyte’s FY20 trading statement shows 21% revenue growth to $26.2m (H220 up 15% to $15.3m), despite COVID impacts. Potential pre-commercialisation milestones have increased from >$800m to >$950m, with 140+ partnered programmes and 100+ covered by clinical licences. This strong performance accompanies recognition of the role of MaxCyte’s technology platform and know-how in enabling next-generation cell and gene therapies. Momentum is expected to flow into 2021, with continued revenue growth and

Companies: MaxCyte, Inc.

Trinity Delta

MaxCyte, Inc.

Company Profile

Research, Charts & Company Announcements

Research Tree provides access to ongoing research coverage, media content and regulatory news on MaxCyte, Inc.. We currently have 179 research reports from 7 professional analysts.

Latest News/RNS

(more news)
Date Source Announcement
10Apr24 13:05 RNS MaxCyte, Inc. - Notice of Results
03Apr24 07:00 RNS MaxCyte, Inc. - Total Voting Rights and Block Listing Return
02Apr24 13:05 RNS MaxCyte, Inc. - Signing of Strategic Platform License
02Apr24 07:00 RNS MaxCyte, Inc. - Exercise of options and PDMR dealing
20Mar24 10:16 RNS MaxCyte, Inc. - Grant of Options, RSUs and PSUs and PDMR Dealing
20Mar24 10:05 RNS MaxCyte, Inc. - Grant of Options, RSUs and PSUs and PDMR Dealing
13Mar24 07:05 RNS MaxCyte, Inc. - Filing of form 10-K for FY ended December 31, 2023
Get free RNS email alerts

  • Frequency of research reports

     

  • Research reports on

    MaxCyte, Inc.

  • Providers covering

    MaxCyte, Inc.